18F-Fluciclovine PET Imaging for Brain Metastasis
This study is for adults (18 and older) who have had surgery for brain metastasis (cancer that has spread to the brain) and are also planning to have stereotactic radiosurgery (a type of radiation therapy). The study aims to see if a special imaging agent called 18F-Fluciclovine, used with a PET/CT scan, can help doctors better see the extent of the tumor after surgery and detect if the cancer returns. This imaging agent is still being investigated for use in brain metastases. The study will measure how well the imaging agent helps define the tumor area and how much of the agent the tumor takes up, at 3 weeks, 6 months, and 12 months after treatment. The current recruitment status is unclear.
- Study design
- This is an interventional study planning to enroll 20 participants. It is not specified if it is randomized or blinded.
- What's involved
- Participants will receive an intravenous injection of 18F-Fluciclovine after fasting for at least four hours, followed by a PET/CT brain scan.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for changes in tumor volume and PET scan results at 3 weeks, 6 months, and 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Rupesh R Kotecha, M.D. · PRINCIPAL_INVESTIGATOR · Miami Cancer Institute/Baptist Health South Florida
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- Change in conformality index of tumor target volume delineation3 weeks, 6 and 12 months
The tumor target volume (post-operative cavity and any residual or recurrent disease) will be delineated by post-operative MRI only. A second target volume will be generated using the 18F-Fluciclovine PET-defined volume. The conformality index is calculated by comparing the PET-defined tumor volume with MRI-defined tumor volume. Non-overlapping and overlapping regions regions of PET tumor volume and MRI tumor volume will be used to calculate conformality indices.
- Change in PET scan standardized uptake value (SUV) parameters3 weeks, 6 and 12 months
The standardized uptake value (SUV) parameters of SUVpeak, SUVmean, and SUVmax will be measured to determine if they correlate tumor volume and can predict risk of recurrence.